2006 Technology Innovation Award of the Year in the field of In Vitro Diagnostics. bioMérieux has been the proud recipient of 2006 Technology Innovation of the Year award in the field of in vitro diagnostics. After extensive evaluation, Frost & Sullivan, an industry-leading global growth consulting company, chose bioMérieux for their development of the NucliSENS easyMAG system. The NucliSENS easyMAG is a breakthrough platform based on the company’s proprietary technologies and features premium nucleic acid extraction quality and enhanced productivity through highly accessible instrumentation.
ExonHit and bioMérieux reach an important research milestone in the molecular detection of breast cancer from blood samples
29 März, 2006
ExonHit Therapeutics, a French drug and diagnostic discovery company, and bioMérieux, a major player in the field of in vitro diagnostics, announce today that they have reached an important research milestone in the diagnosis of breast cancer.
bioMérieux launches an avian flu test for research purposes
02 Februar, 2006
As a major player in the field of in vitro diagnostics, bioMérieux confirms its commitment to the fight against emerging diseases and launches its avian flu detection test.
bioMérieux Editions publishes a book on hospital-acquired infections
09 November, 2005
bioMérieux annonce la parution d’un ouvrage consacré aux Infections Liées aux Soins (ILS). Ce livre a été élaboré par les professeurs Marie-Laure Joly-Guillou et Bernard Régnier. Le Docteur Jean Carlet en a signé la préface.
bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration
13 Oktober, 2005
bioMérieux and ExonHit announced today that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.
DiagnoSwiss and bioMérieux announce that they have signed an exclusive license agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics
27 Juli, 2005
Monthey (Switzerland) – bioMérieux and DiagnoSwiss announced today that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics.
Hepanostika® HBsAg Ultra – New “ultra”-sensitive test for Hepatitis B infection from bioMérieux
05 Juli, 2005
bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of its new microelisa assay for the detection of hepatitis B surface antigen. Hepanostika® HBsAg Ultra is officially presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) currently being held from July 2-6 in Athens, Greece.
Hospices Civils de Lyon and bioMérieux inaugurate a joint immunogenomics and inflammation unit
23 Juni, 2005
Hospices Civils de Lyon (HCL) and bioMérieux will inaugurate today the “HCL-bioMérieux” joint unit dedicated to research in immunogenomics and inflammation. The unit is headed by Prof. Pierre Miossec and Bruno Mougin.